Sevabertinib First-Line NMPA Nod Masks Single-Arm Evidence and TKI Duel

China Approves Sevabertinib as First-Line Therapy for HER2-Mutant NSCLC

Bayer announced that China's National Medical Products Administration (NMPA) has granted marketing authorization for sevabertinib as a first-line therapy for adult patients with unresectable, locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2 (ERBB2) activating mutations. This approval is based on results from the Phase I/II SOHO-01 trial, which showed an Objective Response Rate (ORR) of 75% in a cohort of 73 treatment-naïve patients, including 6% complete responses and 70% partial responses. Furthermore, 73% of responders maintained their response for at least six months. This milestone follows earlier accelerated approvals by the U.S. FDA and Japan's Ministry of Health, Labor, and Welfare for the same indication, addressing a subtype of lung cancer with poor prognosis and limited treatment options.

• The NMPA's marketing authorization for sevabertinib as a first-line therapy for HER2-mutant NSCLC in China marks a significant regulatory achievement. This approval was supported by the Center for Drug Evaluation (CDE) granting Breakthrough Therapy Designation, underscoring the urgent unmet medical need for effective treatments in this patient population, particularly for a distinct subtype that often affects people who have never smoked.
• The approval is primarily based on compelling efficacy data from the Phase I/II SOHO-01 trial, specifically in a cohort of 73 treatment-naïve patients. Sevabertinib demonstrated a high Objective Response Rate (ORR) of 75%, with 6% achieving complete responses and 70% partial responses, indicating substantial tumor shrinkage. The safety profile observed was consistent with previous findings.
• A crucial aspect of sevabertinib's efficacy is the durability of response, with 73% of responders maintaining their clinical benefit for at least six months. This Chinese approval complements earlier accelerated approvals by the U.S. FDA in September 2026 and Japan's MHLW in August 2026, establishing sevabertinib as a globally recognized first-line targeted therapy for advanced HER2-mutant NSCLC.

Addressing the Urgent Unmet Need in HER2-mutant NSCLC

Current management of advanced HER2-mutant non-small cell lung cancer (NSCLC) relies on platinum-pemetrexed-based chemotherapy, eventually in combination with immunotherapy, while targeted options have shown mixed results. Despite recent progress with antibody-drug conjugates (ADCs) targeting HER2, particularly trastuzumab deruxtecan, significant efficacy, safety and sequencing gaps persist.

• Unsatisfactory activity of pan-HER tyrosine kinase inhibitors: Different pan-HER tyrosine kinase inhibitors have been evaluated in limited phase II trials, yielding generally unsatisfactory outcomes, although certain genotypes demonstrated some clinical benefit.

• Substantial toxicity burden limiting dose intensity: In ZENITH20-2, grade 3 or higher treatment-related adverse events with poziotinib (16 mg) once daily included rash (48.9%), diarrhea (25.6%), and stomatitis (24.4%), with poziotinib dose reductions in 76.7% of patients, median relative dose intensity of 71.5%, and permanent treatment discontinuation because of treatment-related adverse events in 13.3% of patients. For trastuzumab deruxtecan, interstitial lung disease (ILD) remains a notable adverse event, with improved tolerability observed at the lower dose of 5.4 mg/kg, and multidisciplinary strategies are also used to manage T-DXd associated adverse events. Myelosuppression requiring careful monitoring has also been reported, including grade 3 myelosuppression leading to discontinuation and subsequent grade 4 white blood cell abnormality, granulocytopenia, platelet deficiency, intracranial hemorrhage and gastrointestinal hemorrhage.

• Central nervous system disease remains an unmet need: Efficacy in treating central nervous system metastases has been uncertain due to concerns over blood-brain barrier penetration and the lack of dedicated CNS-specific evaluations in clinical trials, compounded by variability in trial designs, limited number of patients with untreated CNS disease, and a lack of CNS-specific endpoints, despite emerging intracranial activity with trastuzumab-deruxtecan and high incidence of brain metastasis with significant impact on patient outcomes.

• Limited benefit of sequential HER2-directed ADCs and undefined resistance mechanisms: T-DXd retains clinical activity after prior T-DM1 use, whereas T-DM1 has limited efficacy after prior T-DXd in HER2-mutant NSCLC, with no confirmed responses observed, median real-world progression-free survival of 3.3 months (95% CI, 1.9-5.6) and median overall survival of 9.2 months (95% CI, 4.9-NR) for T-DM1 post-T-DXd versus 37.5% confirmed partial responses, median real-world progression-free survival of 5.2 months (95% CI, 4.1-NR) and median overall survival of 25.0 months (95% CI, 8.2-NR) for T-DXd post-T-DM1, highlighting the need to understand mechanisms of response and resistance to inform treatment strategies using sequential ADCs.

SOHO-01: The Clinical Evidence Behind Sevabertinib's Approval

Recent studies in HER2-mutant metastatic non-small cell lung cancer have evaluated antibody-drug conjugates and selective tyrosine kinase inhibitors across clinical trial and real-world settings. Trastuzumab deruxtecan has shown consistent response rates around 50-57% with interstitial lung disease as the principal safety concern, while newer agents such as zongertinib and poziotinib have demonstrated activity with distinct toxicity profiles.

• DESTINY-Lung02 — trastuzumab deruxtecan (T-DXd) 5.4 or 6.4 mg/kg once every 3 weeks: In 102 patients at 5.4 mg/kg and 50 patients at 6.4 mg/kg with previously treated HER2-mutant metastatic NSCLC, confirmed objective response rate was 50.0% (51/102; 39.9%-60.1%) and 56.0% (28/50; 41.3%-70.0%). Median treatment duration was 7.7 months (3.7-14.4) and 8.3 months (2.8-13.1); drug-related grade ≥3 treatment-emergent adverse events occurred in 39.6% (40/101) and 60.0% (30/50), with nausea most common (67.3% [68/101], 82.0% [41/50]). Adjudicated drug-related interstitial lung disease occurred in 14.9% (15/101) and 32.0% (16/50), mostly grade 1/2; one grade 5 in each arm.

• DESTINY-Lung05 — trastuzumab deruxtecan 5.4 mg/kg once every 3 weeks in patients from China: In 72 patients with HER2 exon 19/20 mutation metastatic NSCLC with disease progression on/after ≥1 prior anticancer therapy, confirmed objective response rate was 56.9% (95% confidence interval [CI] 44.7-68.6). Median progression-free survival and overall survival were 9.9 months (95% CI 7.1-16.5) and 21.0 months (95% CI 17.5-not calculable). Grade ≥3 drug-related adverse events occurred in 40 (55.6%) patients; adjudicated drug-related interstitial lung disease/pneumonitis events were observed in 9 (12.5%) patients (n = 8 grade 1/2; n = 1 grade 3).

• TRACER/HERTras Real-World Cohort — trastuzumab deruxtecan outside clinical trials: Among 168 patients (median age 62 years; 59% female; 56% never-smokers), objective response rate was 54.8% (95%CI, 46.9-62.4) and disease control rate 88.7% (95%CI, 82.9-93.1). Median progression-free survival was 7.2 months (95%CI, 6.2-9.7) and overall survival 18.3 months (95%CI, 13.3-24.8); patients with measurable brain metastases (n=27) had an intracranial objective response rate of 74.1% (95%CI, 53.7-88.9), including 25.9% complete responses. Grade ≥3 treatment-related adverse events occurred in 32% of patients; interstitial lung disease/pneumonitis occurred in 14% (four fatal cases).

• Beamion LUNG-1 Phase Ia — zongertinib (BI 1810631) twice a day (15-150 mg) or once daily (60-360 mg): In 54 patients with NSCLC, confirmed investigator-assessed overall response rate was 35% (95% CI, 24 to 49); activity was observed in patients with A775_G776insYVMA (ORR, 38%) and those who had received previous HER2-directed therapy (ORR, 28%). In patients with NSCLC receiving zongertinib once daily, median progression-free survival was 17.2 months (95% CI, 8.3 to NR). Treatment-related adverse events (any/grade ≥3) occurred in 82%/10% of patients; most common were diarrhea (50%/1%), rash (16%/2%), anemia (10%/0%), decreased appetite (10%/1%), and increased alanine transaminase (10%/4%).

• ZENITH20-2 — poziotinib 16 mg once daily: In 90 previously treated patients with NSCLC with HER2 exon 20 insertions, objective response rate was 27.8% (95% CI, 18.9 to 38.2); 25 of 90 patients achieved a partial response. Disease control rate was 70.0% (95% CI, 59.4 to 79.2); median progression-free survival was 5.5 months (95% CI, 3.9 to 5.8) and median duration of response was 5.1 months (95% CI, 4.2 to 5.5). Grade 3 or higher treatment-related adverse events included rash (48.9%), diarrhea (25.6%), and stomatitis (24.4%).

Sevabertinib's Place in the Evolving HER2-mutant NSCLC Landscape

Earlier published trial data established proof of concept for pan-HER tyrosine kinase inhibitors in HER2-mutant non-small cell lung cancer, with modest durability and EGFR-mediated toxicity. In a multicenter, single-arm, phase II trial, pyrotinib 400 mg/day produced an objective response rate of 19.2% (95% CI, 11.2-30.0), 6-month progression-free survival rate of 49.5% (95% CI, 39.2-60.8), median progression-free survival of 5.6 months (95% CI, 2.8-8.4) and median overall survival of 10.5 months (95% CI, 8.7-12.3). In HER2-amplified disease, pyrotinib produced a 6-month progression-free survival rate of 51.9% [95% confidence interval (CI), 34.0-69.3], median progression-free survival of 6.3 months (95% CI, 3.0-9.6 months), median overall survival of 12.5 months (95% CI, 8.2-16.8 months) and confirmed objective response rate of 22.2% (95% CI, 10.6%-40.8%). Poziotinib showed similar activity in previously treated HER2 exon 20 insertion disease in ZENITH20 cohort 2, with objective response rate of 27.8% (95% CI, 18.9 to 38.2), disease control rate of 70.0% (95% CI, 59.4 to 79.2), median progression-free survival of 5.5 months (95% CI, 3.9 to 5.8) and median duration of response of 5.1 months (95% CI, 4.2 to 5.5), while treatment-naive patients in ZENITH20-C4 achieved objective response rate of 39% (95% CI: 28%-50%; 31 of 80), disease control rate of 73% (95% CI: 61%-82%; 58 of 80), median duration of response of 5.7 (95% CI: 4.6-11.9) months and median progression-free survival of 5.6 (95% CI: 5.4-7.3) months.

The landscape shifted with the HER2-directed antibody-drug conjugate trastuzumab deruxtecan. In DESTINY-Lung01 in metastatic HER2-mutant non-small cell lung cancer refractory to standard treatment, trastuzumab deruxtecan 6.4 mg per kilogram produced centrally confirmed objective response in 55% of the patients (95% confidence interval [CI], 44 to 65), median duration of response of 9.3 months (95% CI, 5.7 to 14.7), median progression-free survival of 8.2 months (95% CI, 6.0 to 11.9) and median overall survival of 17.8 months (95% CI, 13.8 to 22.1), with grade 3 or higher drug-related adverse events in 46% of patients and adjudicated drug-related interstitial lung disease in 26% of patients. With extended follow-up in DESTINY-Lung05 in patients from China with HER2 exon 19/20 mutation and disease progression on/after ≥ 1 prior anticancer therapy, trastuzumab deruxtecan 5.4 mg/kg once every 3 weeks produced confirmed objective response rate of 56.9% (95% confidence interval [CI] 44.7-68.6), median progression-free survival of 9.9 months (95% CI 7.1-16.5) and overall survival of 21.0 months (95% CI 17.5-not calculable), with grade ≥ 3 drug-related adverse events in 40 (55.6%) patients and adjudicated drug-related interstitial lung disease/pneumonitis in 9 (12.5%) patients (n = 8 grade 1/2; n = 1 grade 3). Real-world data reinforced systemic and intracranial activity, with the TRACER/HERTras cohort reporting objective response rate of 54.8% (95%CI, 46.9-62.4), disease control rate of 88.7% (95%CI, 82.9-93.1), median progression-free survival of 7.2 months (95%CI, 6.2-9.7), overall survival of 18.3 months (95%CI, 13.3-24.8) and intracranial objective response rate of 74.1% (95%CI, 53.7-88.9) in patients with measurable brain metastases (n=27), with interstitial lung disease/pneumonitis in 14% (four fatal cases) of patients.

More recent development has focused on chemotherapy-sparing combinations and HER2-selective inhibition against a historical baseline of platinum-based chemotherapy with or without immune checkpoint inhibitor. In previously treated HER2-altered metastatic disease, pyrotinib 400 mg plus apatinib 250 mg once daily in PATHER2 produced investigator-assessed objective response rate of 51.5% (17/33; 95% CI, 33.5 to 69.2%), disease control rate of 93.9% (31/33; 95% CI, 79.8 to 99.3%), median duration of response of 6.0 (95% CI, 4.4 to 8.6) months, progression-free survival of 6.9 (95% CI, 5.8 to 8.5) months and overall survival of 14.8 (95% CI, 10.4 to 23.8) months. As first-line therapy in stage IIIB-IV disease harboring de novo HER2 mutations or amplification, the same regimen produced objective response rate of 72.7 % (95 % CI, 49.8-89.3), disease control rate of 95.5 % (95 % CI, 77.2-99.9) and median progression-free survival of 10.7 months (95 % CI, 6.6-14.8) with median follow-up of 37.0 months (95 % CI, 36.1-37.9). Zongertinib, an oral, irreversible, HER2-selective tyrosine kinase inhibitor that suppresses oncogenic HER2 signaling while largely sparing wild-type EGFR, achieved confirmed objective response rate of 71% and median progression-free survival of 12.4 months in previously treated HER2 tyrosine kinase domain-mutant non-small cell lung cancer in Beamion LUNG-1. These results contrast with historical real-world outcomes before approved targeted therapy, where median real-world progression-free survival in first-line was 5.5 (4.8, 6.2) months and 3.0 (2.3, 4.2) months in second-line, and median real-world overall survival in first-line was 13.2 (10.6, 18.4) months and 8.2 (6.6, 13.2) months in second-line.